Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Herefordshire based Founder operating in the Health Care space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Karl Peggs
Founder of Achilles Therapeutics
Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London. After taking the position of Senior Lecturer at UCL in 2003 and Head of Adult Stem Cell Transplantation Services, UCLH, he spent over 2 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute and his research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH. Karl was trained at the John Radcliffe Hospital, Oxford, Addenbrooke’s Hospital, Cambridge, and UCH, London.
Follow Karl Peggs:
About Achilles Therapeutics: Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Mike Trower
Founder, Chief Scientific Officer & Chief Operating Officer of NeRRe Therapeutics
Mike is Co-founder and Chief Scientific Officer of KaNDy Therapeutics. It was Mike’s advocacy of the dual mechanism neurokinin-1,3 receptor antagonism, offered by NT-814, to present a novel and potentially transformational non-hormonal therapy for treatment of symptoms of the menopause and other related Women’s Health conditions which led to NT-814 being spun out of NeRRe Therapeutics to create KaNDy Therapeutics in 2017. Mike has broad knowledge of neurokinin receptor biology and, in particular, the emerging science that has established the pivotal role these systems play in neuroendocrinology and female sex-hormone related disorders. Mike is also Co-founder and CSO of NeRRe Therapeutics whose focus is on developing the neurokinin-1 receptor antagonist orvepitant to treat neuronal hypersensitivity disorders including chronic refractory cough. Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position, Mike successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets. Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.
Follow Mike Trower:
About NeRRe Therapeutics: NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Peter Kennerley
Chief Executive Officer & Founder of Emas Pharma
Peter joined the pharmaceutical industry in 1987 after several years in the NHS as an anaesthetist. Since then, he has worked in senior positions for major as well as small Pharma companies, with duties ranging from drug development to medical affairs and he has brought several products to market, both as blockbusters and as niche products. Since establishing Emas, he has chaired expert panels, established drug safety processes and overseen successful regulatory procedures for a range of products from radiolabelled monoclonal antibodies to mast cell histamine release inhibitors and from glucoside inhibitors to proton pump inhibitors. He retains a determination that Emas should avoid the usual service company clichés and simply demonstrate its worth through the highest possible quality support at a competitive cost.
Follow Peter Kennerley:
About Emas Pharma: Emas Pharma provides pharmaceutical and device development services worldwide and specializes in partnering with specialist pharma.
Scott Crowe
Founder and CSO of VHSquared
Follow Scott Crowe:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Mel Vinton
Chief Technology Officer & Co-Founder of Inotec AMD
Mel Vinton is a Chief Technology Officer & Co-Founder at Inotec AMD.
Follow Mel Vinton:
About Inotec AMD: Inotec AMD is a medical device company.
